| Recruiting | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple NCT06517017 | University of Utah | Phase 2 |
| Recruiting | A Study of CT0596 in Plasma Cell Leukemia NCT06988059 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Recruiting | Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM NCT07109323 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | The Norwegian Immunotherapy in Multiple Myeloma Study NCT06855121 | St. Olavs Hospital | — |
| Not Yet Recruiting | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell L NCT06655519 | Peking University People's Hospital | Phase 1 |
| Recruiting | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Tr NCT05979363 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Active Not Recruiting | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients NCT05823571 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or NCT06045091 | Hrain Biotechnology Co., Ltd. | EARLY_Phase 1 |
| Recruiting | Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous St NCT05405387 | University of Utah | Phase 2 |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leuk NCT05870917 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05822037 | The First Affiliated Hospital of Soochow University | N/A |
| Recruiting | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05759793 | Nanjing IASO Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | European Myeloma Network (EMN) Sample Project NCT06237803 | European Myeloma Network B.V. | — |
| Recruiting | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphod NCT05092451 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05219721 | Chunrui Li | Phase 1 |
| Not Yet Recruiting | Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem C NCT05054478 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Recruiting | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH NCT05283993 | Peking University First Hospital | — |
| Recruiting | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry NCT05556928 | University of Alabama at Birmingham | — |
| Withdrawn | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Tre NCT03591744 | City of Hope Medical Center | Phase 1 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Rel NCT03389347 | University of Washington | N/A |
| Recruiting | Registry for Adults With Plasma Cell Disorders (PCD's) NCT03717844 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients NCT04008888 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myelom NCT02547662 | Mayo Clinic | Phase 2 |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patie NCT02506959 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Tr NCT02504359 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma NCT02315157 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed NCT01729091 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leu NCT01372540 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Ce NCT01435720 | Senesco Technologies, Inc. | Phase 1 / Phase 2 |
| Completed | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Don NCT01163357 | City of Hope Medical Center | Phase 1 |
| Unknown | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia NCT01328236 | Clinical Service, China | Phase 2 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma NCT00821249 | Pfizer | Phase 1 / Phase 2 |
| Terminated | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning NCT00615589 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transpl NCT00307086 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Available | Expanded Access to Venetoclax NCT03123029 | AbbVie | — |